Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to $7.4 million.

  • Protalix BioTherapeutics' Total Non-Current Liabilities rose 5105.99% to $7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.4 million, marking a year-over-year increase of 5105.99%. This contributed to the annual value of $4.6 million for FY2024, which is 1405.81% down from last year.
  • As of Q3 2025, Protalix BioTherapeutics' Total Non-Current Liabilities stood at $7.4 million, which was up 5105.99% from $4.5 million recorded in Q2 2025.
  • In the past 5 years, Protalix BioTherapeutics' Total Non-Current Liabilities ranged from a high of $46.5 million in Q4 2021 and a low of $4.4 million during Q1 2025
  • In the last 5 years, Protalix BioTherapeutics' Total Non-Current Liabilities had a median value of $7.4 million in 2021 and averaged $18.9 million.
  • Within the past 5 years, the most significant YoY rise in Protalix BioTherapeutics' Total Non-Current Liabilities was 44754.62% (2021), while the steepest drop was 8876.89% (2021).
  • Over the past 5 years, Protalix BioTherapeutics' Total Non-Current Liabilities (Quarter) stood at $46.5 million in 2021, then decreased by 26.93% to $34.0 million in 2022, then tumbled by 84.31% to $5.3 million in 2023, then fell by 14.06% to $4.6 million in 2024, then soared by 61.64% to $7.4 million in 2025.
  • Its Total Non-Current Liabilities stands at $7.4 million for Q3 2025, versus $4.5 million for Q2 2025 and $4.4 million for Q1 2025.